Christian Gessner

Leipzig, SN 04103, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Early and continued asthma control up to week 24 in patients with severe, uncontrolled asthma treated with tezepelumab: Initial results of the real-world ASCENT study.

Early and continued asthma control up to week 24 in patients with severe, uncontrolled asthma treated with tezepelumab: Initial results of the real-world ASCENT study.

Journal: Respiratory medicine

Published: December 19, 2025

Early and continued asthma control up to week 24 in patients with severe, uncontrolled asthma treated with tezepelumab: Initial results of the real-world ASCENT study.

Early and continued asthma control up to week 24 in patients with severe, uncontrolled asthma treated with tezepelumab: Initial results of the real-world ASCENT study.

Journal: Respiratory medicine

Published: December 19, 2025

Real-World Effectiveness and Safety of Single Inhaler Triple Therapy with Beclometasone/ Formoterol/ Glycopyrronium in Moderate to Severe Asthma: TriMaximize Study.

Real-World Effectiveness and Safety of Single Inhaler Triple Therapy with Beclometasone/ Formoterol/ Glycopyrronium in Moderate to Severe Asthma: TriMaximize Study.

Journal: Journal of asthma and allergy

Published: November 17, 2025

Inhaled anti-thymic stromal lymphopoietin antibody fragment, ecleralimab, in severe asthma: A placebo-controlled, multicenter, double-blind, randomized, phase 2b clinical trial.

Inhaled anti-thymic stromal lymphopoietin antibody fragment, ecleralimab, in severe asthma: A placebo-controlled, multicenter, double-blind, randomized, phase 2b clinical trial.

Journal: American journal of respiratory and critical care medicine

Published: June 20, 2025

Inhaled anti-thymic stromal lymphopoietin antibody fragment, ecleralimab, in severe asthma: A placebo-controlled, multicenter, double-blind, randomized, phase 2b clinical trial.

Inhaled anti-thymic stromal lymphopoietin antibody fragment, ecleralimab, in severe asthma: A placebo-controlled, multicenter, double-blind, randomized, phase 2b clinical trial.

Journal: American journal of respiratory and critical care medicine

Published: June 20, 2025

Effectiveness and safety of Atezolizumab in patients with locally-advanced or metastatic non-small cell lung cancer after prior chemotherapy under real-life conditions in Germany: The Non-interventional Study HYPERION.

Effectiveness and safety of Atezolizumab in patients with locally-advanced or metastatic non-small cell lung cancer after prior chemotherapy under real-life conditions in Germany: The Non-interventional Study HYPERION.

Journal: Cancer treatment and research communications

Published: October 25, 2024

Diagnosis and treatment of asthma: a guideline for respiratory specialists 2023 - published by the German Respiratory Society (DGP) e. V.

Diagnosis and treatment of asthma: a guideline for respiratory specialists 2023 - published by the German Respiratory Society (DGP) e. V.

Journal: Pneumologie (Stuttgart, Germany)

Published: March 21, 2024

Real-world use of inhaled corticosteroid/formoterol as needed in adults with mild asthma: the PRIME study.

Real-world use of inhaled corticosteroid/formoterol as needed in adults with mild asthma: the PRIME study.

Journal: ERJ open research

Published: February 23, 2024

Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial.

Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial.

Journal: American journal of respiratory and critical care medicine

Published: July 06, 2023

Diagnosis and treatment of asthma: a guideline for respiratory specialists 2023 - published by the German Respiratory Society (DGP) e. V.

Diagnosis and treatment of asthma: a guideline for respiratory specialists 2023 - published by the German Respiratory Society (DGP) e. V.

Journal: Pneumologie (Stuttgart, Germany)

Published: July 05, 2023

The influence of anti-cancer therapies on lymphocyte subpopulations of lung cancer patients.

The influence of anti-cancer therapies on lymphocyte subpopulations of lung cancer patients.

Journal: Frontiers in immunology

Published: June 12, 2023

Asthma: an update of drug therapy in adults

Asthma: an update of drug therapy in adults

Journal: MMW Fortschritte der Medizin

Published: May 31, 2023

Showing 1-12 of 35

Last Updated: 09/26/2026